Navigate Fool.com
Will PARD beat
the market?

Poniard Pharmaceuticals, Inc. (NASDAQOTH: PARD)

Community Rating: 1 Star: Ominous

0.29 0.00 (0.00%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.00
Previous Close $0.29
Daily Range $0.00 - $0.00
52-Week Range $0.20 - $0.57
Market Cap $433,277.76
P/E Ratio -0.02
Dividend (Yield) $0.00 (0.0%)
Volume 0
Average Daily Volume 886
Current FY EPS $0.00

How do you think PARD
will perform against the market?

Top PARD Bull/Bear Pitches


noirblood (< 20)
Submitted August 10, 2010

Lost a few points here with impatient timing, but I expect to gain them back and then some before the end of 2010. Baby bios are always hit or miss, but under a dollar PARD is worth a gamble. Their e … More

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted January 21, 2011

I've worked Poniard hard to assume my rightful position at the top of the leaderboard, since my original negative call on the SPEAR trial in 2009 couldn't compete with the players who stochastically r … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Cashing In on Obamacare

If you stop grousing for a few minutes, you might find a way to make some money.

Registration Effectiveness Orders Issued By The SEC

UPDATE 1-Poniard says resuming regulatory efforts on key drug

UPDATE 1-Poniard suspends regulatory efforts on key drug

UPDATE 1-Poniard cuts half of workforce; names new CEO

Poniard shares fall after cancer drug shows lower survival

UPDATE 1-Poniard shares up on positive colorectal cancer data

UPDATE 1-Poniard cancer drug misses study goal; shares plunge

5 Cold Stocks Heating Up

Investors are warming up to these previously unloved companies.

10 Stocks to Shake the Market

Forget the automakers. A truck maker was one of the top movers.

See More PARD News...





Poniard Pharmaceuticals, Inc. (PARD) Description

A biotechnology company focused on the discovery, development and commercialization of cancer therapy products. Website:

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks